Bioavailability of Oral Ondansetron in Dogs: A Crossover Study.

Amanda Garrick, Kristin Zersen, Daniel Gustafson, Jessica Quimby, Amanda Diaz, Sarah Shropshire

Abstract read

In one paragraph

Article in Journal of veterinary pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

The Pharmacokinetics of Intravenous and Subcutaneous Ondansetron in Female Beagle Dogs.Journal of veterinary pharmacology and therapeutics · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amanda GarrickClinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA.ORCID https://orcid.org/0009-0005-0693-6875

Kristin ZersenClinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA.ORCID https://orcid.org/0000-0003-0327-8537

Daniel GustafsonClinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA.

Jessica QuimbyClinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA.

Amanda DiazClinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA.

Sarah ShropshireClinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA.

Funding

Colorado State University

6 · The paper itself

Abstract

The purpose of this study was to evaluate the pharmacokinetics of oral (PO) ondansetron compared to intravenous (IV) ondansetron in eight healthy client-owned dogs. Dogs were randomized to one of two protocols in a crossover design, receiving PO or IV ondansetron at a dose of 1 mg/kg on Day 0 and the opposite formulation at an equal dose on Day 7. Plasma was collected at baseline and 1, 2, 4, and 8 h post administration. Ondansetron concentrations were measured utilizing liquid chromatography/mass spectrometry. For IV administration, AUC

Indexed as

AntiemeticsOndansetronAdministration, OralAnimalsArea Under CurveBiological AvailabilityCross-Over StudiesDogsFemaleHalf-LifeMaleAntiemeticsOndansetron

Identifiers

PMID40924364

DOI10.1111/jvp.70024

PMCPMC12796776

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.